NCT04634552: Phase 2 - A Study of Talquetamab in Participants With Refractory Multiple Myeloma
NCT04674813: Phase 1 - A Study of CC-95266 in Subjects With Relapsed and/or Refractory Myeloma
NCT04570631: Phase 1: Eftozanermin Alfa (ABBV-621) + Bortezomib and Oral Dexamethasone RRMM
NCT04582539: Phase 1/2: Safety and Tolerability of INCB000928 in Myelodysplastic Synd. or Myeloma
NCT04680468: Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant & Maintenance
Myeloma Canada: Patient Handbook - MGUS and Smoldering Multiple Myeloma
NCT04354246: Phase 1: COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies
NCT04674514: Phase 1/2: APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS RRMM Myeloma
NCT04392037: Phase 2: Iberdomide Combined With Low-dose Cyclophosphamide and Dexamethasone (ICON)
NCT04458831: A Non-interventional, Multinational, Observational study With Isatuximab in RRMM
FDA Approved for RRMM: Xpovio (selinexor) tablets + Velcade (Bortezomib) and Dexamethasone
NCT04635735: Phase 1/2: Study of Ipilimumab After Stem Cell Transplantation in People With RRMM
NCT04634435: Phase 1/2: Auto Memory-like NK Cell + BHV-1100 (Formerly KP1237), Low Dose IL-2 in NDMM
NCT04555551:Phase 1 - MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for Multiple Myeloma
CAR T-Cell Therapy: ASCO’s 2018 Advance of the Year
NCT04497961: Phase 2: A Study of Health-Related Quality of Life with Daratumumab or Lenalidomide
NCT04093596: Phase 1 - ALLO-715 BCMA Allogenic CAR T Cells in relapsed Multiple Myeloma (UNIVERSAL)
NCT04405167: Phase 1: Tasquinimod for the Treatment of Relapsed or Refractory Myeloma
NCT04309981: Phase 1/2: Humanized CART Directed Against BCMA (ARI0002h) in RRMM Multiple Myeloma
NCT04512235: Phase 3: To Evaluate Effectiveness & Safety of CAEL-101 in Stage IIIa AL Amyloidosis
Myeloma Canada: Patient Handbook - Myeloma Bone Disease
NCT04566328: Phase 3 - Testing the Use of Combination Therapy in NDMM, the EQUATE Trial - EAA181
NCT04613557: Phase 1: Safety, Activity and Cell Kinetics of CYAD-211 in RRMM Myeloma (IMMUNICY-1)
NCT04508790: Phase 2: Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of RRMM Myeloma